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Abstract 
Purpose: To explore the anti-diabetic effects of Moringa oleifera extracts and fractions, and to identify 
their active/marker compounds.  
Methods: Five different aqueous ethanol extracts (95, 75, 50, 25 %v/v and 100 % water) of Moringa 
oleifera were given orally to normal rats to assess their hypoglycemic activities and effect on 
intraperitoneal glucose tolerance test (IPGTT) data. Rats with streptozotocin-induced diabetes were 
used to assess acute and sub-chronic anti-hyperglycemic activities. The most active extract was further 
subjected to liquid-liquid fractionation into hexane, chloroform, ethyl acetate, butanol, and water; these 
fractions were screened for anti-diabetic activities. The most active extract, and fractions thereof, were 
then subjected to qualitative and quantitative phytochemical analysis. Standardization was achieved via 
thin layer chromatography (TLC) and high-performance liquid chromatography (HPLC), and used to 
identify marker compounds.  
Results: Of all the extracts and fractions, 95 % (v/v) ethanol extract (at 1,000 mg/kg) and the butanol 
fraction thereof (at 500 mg/kg) were the most active, reducing blood glucose concentration after one-
time (acute) administration to diabetic rats (p < 0.01). No significant hypoglycemic activity was apparent, 
and the materials had no effect on IPGTT performance by normal rats. TLC and HPLC identified 
quercetin 3-β-D-glucoside, kaempferol-3-O-glucoside, and cryptochlorogenic acid.  
Conclusion: An M. oleifera leaf extract exhibited anti-hyperglycaemic activity in diabetic rats only. This 
effect was likely attributable to cryptochlorogenic acid, quercetin 3-β-D-glucoside, and kaempferol 3-O-
glucoside.   
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Glucose homeostasis is the balance between 
glucose production and utilisation by peripheral 
tissues. Insulin promotes glucose uptake by cells 
[1]. An insulin deficiency combined with insulin 
resistance is responsible for diabetes mellitus [2]. 
The World Health Organization has observed 
that diabetes has become a major problem, and 
the number of cases is expected to rise through 
the year 2035 [3]. The prevalence of diabetes is 
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increasing among Malaysians, reaching 23.8 % 
in recent years [4].  
 
Natural products and their derivatives constitute 
ca. 50 % of all anti-diabetics. The rate is higher 
when related synthetic materials are considered 
[5], but these materials are costly [6]. Generally, 
various extracts of natural materials are 
subjected to primary screening and the best 
extract is selected [7].  
 
Marker compounds therein are identified using 
standard techniques [8]. High-performance liquid 
chromatography (HPLC) and thin layer 
chromatography (TLC) are valuable 
chromatographic techniques [9] employed to 
identify molecules responsible for therapeutic 
activities [10].  
 
Recently, advances in the isolation and 
identification of active compounds in medicinal 
plants have featured fractionation-guided 
targeting.  
 
Therefore, we identified active anti-diabetic 
compounds in extracts and fractions of Moringa 
oleifera. Our findings will aid future drug 




Apparatus, chemicals, and drugs 
 
A rotary evaporator (Buchi Labotechnik, CH-
9230 Flawil Switzerland), a WinCATS Planar 
Chromatography Manager (Merck, Germany), 
streptozotocin (Sigma Aldrich Chemical Co, 
USA), acetonitrile and formic acid (Merck, 
Germany), quercetin 3-β-D-glucoside (Sigma 
Aldrich, USA), kaempferol 3-O-glucoside (480-
10-4, Extrasynthese, Genay Cedex), 
cryptochlorogenic acid (Wuhan ChemFaces 
Biochemical Co. Ltd), glibenclamide 5 mg 
(Daonil) and metformine (500 mg; Glucophage; 
Merck, Germany) were used in this study.   
 
Authentication of the plant and preparation of 
extracts  
 
Plant material was purchased from Harbagus 
Sdn. Bhd., Pulau Pinang, Malaysia, and was 
authenticated by Dr Rahmad Zakaria. A voucher 
specimen has been placed in the herbarium of 
School of botany, Universiti Sains Malaysia (no. 
11626). M. oleifera leaves were dried in the 
shade, ground to a powder, and extracted with 
95, 75, 50, and 25 % (v/v) ethanol and 100 % 
water via maceration (Table 1). All extracts were 
concentrated under reduced pressure in a rotary 
evaporator and dried in an oven at 45 ºC. 
Experimental animals  
 
Healthy male adult Sprague Dawley (SD) rats 
aged 8 - 9 weeks (230 ± 30 g body weight) were 
used in the experimental studies. The animals 
were obtained from the Animal Research and 
Service Centre (ARASC), Universiti Sains 
Malaysia and allowed to adapt for seven days in 
the transit room of the School of Pharmaceutical 
Sciences at a temperature of 25 ± 3 °C under a 
12/12-h dark/light cycle. The rats had ad libitum 
access to rat pellets and water. The Animal 
Ethics Committee of Universiti Sains Malaysia 
approved the work (approval no. AEA/2015/612) 
and was performed in compliance with 
international guidelines (NIH) for the care and 
use of animals [11]. 
 
Blood glucose measurement 
 
Blood samples (single drops) were collected by 
nicking the tail vein, and blood glucose (BG) 
levels were determined using a glucometer 





Hypoglycaemia in normoglycaemic rats 
 
Forty-two male SD rats were used to measure 
hypoglycaemic activity. The negative control 
(NC) and positive control (PC) groups were given 
distilled water (10 mL/kg) and water containing 
glibenclamide (10 mg/kg), respectively. The 
treated groups were given 95, 75, 50 and 25 % 
(v/v) ethanol and 100 % water extracts (1,000 
mg/kg orally). After 14 h overnight fasting, fasting 
blood glucose (FBG) levels were determined; the 
treatments were then applied, and glucose levels 
were measured 1, 3, 5 and 7 h later. 
 
Intraperitoneal glucose tolerance test in 
normoglycaemic rats 
 
Normal rats were divided randomly into eight 
groups. One hour after oral administration of all 
treatments, the rats were injected 
intraperitoneally with a glucose load (500 mg/kg 
body weight). BG levels were measured at 0, 15, 
30, 45, 60, 90, and 120 min thereafter. 
  
Anti-hyperglycaemic activity in streptozo-
tocin-treated rats: single-dose study 
 
Diabetes was induced by intraperitoneal injection 
of streptozotocin (45 mg/kg body weight) after 
overnight fasting. Glucose was added to the 
drinking water (to 5 %, w/v) for 12 h to reduce 
mortality caused by hypoglycaemia. BG levels 
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were measured 72 h later. Rats with FBG 
concentrations > 15 mmol/L were considered to 
be diabetic and were used in further studies.  
 
To measure anti-hyperglycaemic activity, rats 
were divided into seven groups. The 
experimental protocol was as described above, 
except that the PC group received metformin 
(500 mg/kg). 
 
Anti-hyperglycaemic activity in streptozo-
tocin-treated rats: multiple-dose study 
 
The groups formed were the same as those 
created for the single-dose study described 
above. Diabetic rats were treated with M. oleifera 
aqueous ethanol extracts (1,000 mg/kg) once 
daily for 14 days. BG levels were determined on 
day-0, 7 and 14 after overnight fasting.  
 
Fractionation (Liquid-liquid extraction) 
 
The most active extract (the 95 % [v/v] ethanol) 
of M. oleifera was subjected to further 
fractionation. The extract was first partitioned 
with distilled water, and then (serially) with 
hexane, chloroform, ethyl acetate, and butanol, 
in a separating funnel. All five fractions (hexane, 
chloroform, ethyl acetate, butanol, and water) 
were concentrated separately under reduced 
pressure in rotary evaporator and dried in an 
oven at 45 °C. 
 
Anti-hyperglycaemic screening of M. 
oleifera fractions in the rat streptozotocin 
model 
 
Seven groups (six rats per group) were used. All 
groups underwent treatment with fractions (500 
mg/kg) suspended in 10 % (v/v) Tween 80. FBG 
levels were determined after administration of 
various fractions and a standard drug at 1, 3, 5, 
and 7 h. 
 
Phytochemical screening of extracts and 
fractions 
 
For qualitative phytochemical screening, samples 
(extracts and fractions) were dissolved in 
dimethyl sulfoxide. Tannins, phenols, saponins, 
flavonoids, alkaloids, terpenoids, and glycosides 
were assayed using standard tests [12,13]. 
 
Thin layer chromatography  
 
Qualitative screening of active compounds was 
performed on 20 × 20-cm silica gel TLC plates 
(Merck). The samples (the 95 % ethanol extract 
and the butanol fraction) were dissolved to 5 
mg/mL and the standards (cryptochlorogenic 
acid, kaempferol-3-O-glucoside, and quercetin 3-
β-D-glucoside) were dissolved to 1 mg/mL. The 
TLC plates were developed in a TLC chamber 
(10 × 10 cm); the mobile phase was ethyl 
acetate: methanol: Acetic acid: water (110: 13.5: 
8: 8 by volume). The plates were sprayed with 
the natural product (NP) reagent and viewed 
under ultraviolet light at 254 and 366 nm with the 
aid of a winCATS Planar Chromatography 
Manager. Rf values were calculated using 
equation 1: 
 
Rf = distance travelled by compound / distance 
travelled by solvent front ………... (1) 
 
HPLC development and validation  
 
A 95 % (v/v) ethanol extract, the butanol fraction 
thereof (1,000 ppm), and standard compound 
(2,000 ppm) stock solutions were prepared in 
methanol, filtered through syringe filter (0.45-µm 
pore size), and analysed on an 1100/1200 HPLC 
plateform (Agilent Technologies, USA) fitted with 
a column thermostat, a quaternary pump, a diode 
array detector, and an agilent 1200 autosampler 
(SL 1). We used a Hypersil Gold C4 column with 
a particle size of 5.0 µm and dimensions of 250.0 
× 4.6 mm (Thermo-Scientific, USA). The solvent 
systems were 0.1 % (v/v) formic acid (B) and 
acetonitrile (C), and elution employed the 
following gradient: 0 - 5 min, B (97 %) and C (3 
%); 5 - 14.5 min, B (80 %) and C (20 %); 14.5 - 
16.5 min, B (97 %) and C (3 %). The injection 
volume was 20 µL, the column flow rate was 1.2 
mL/min, and the run time was 18 min. All 
chromatographic signals were detected at 344 
nm. 
 
Quantification of identified compounds 
 
To quantify cryptochlorogenic acid, quercetin 3-
β-D-glucoside, and kaempferol-3-O-glucoside in 
the active 95 % (v/v) ethanol extract and the 
butanol fraction thereof, the peak heights of 
samples were compared with those of standards. 
 
Evaluation of linearity, accuracy and 
precision 
 
Linearity was checked by evaluating the peak 
heights (in mAU) of standards (12.5 - 200 
µg/mL). Accuracy was evaluated by checking 
agreement between the amounts applied and the 
amounts measured by HPLC. We also evaluated 
the repeatability (precision) of the method. We 
injected three sets of standard mixtures three 
times daily over 3 consecutive days and 
measured intra-day and inter-day accuracy and 
precision.  
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The results are presented as mean ± standard 
deviations and were analyzed by one-way 
analysis of variance with the aid of IBM SPSS 
software, followed by Dunnett’s post hoc test. 
Differences between means were considered to 
be statistically significant at p < 0.05, < 0.01, or < 
0.001. For graphical presentation, GraphPad 




Effect of extracts of Moringa oleifera in 
normal rats 
 
BG concentrations rose after administration of all 
extracts (95, 75, 50, 25 % [v/v] ethanol and 
water) for up to 3 h (compared with FBG levels), 
but declined over the next 4 h (Table 2). No 
significant reduction in glucose concentration 
was observed, except in the glibenclamide group 
(31.81 %). 
 
Effect of different extracts on IPGTT in 
normoglycemic rat 
 
Glibenclamide greatly lowered the BG 
concentration (by 35.52 %) 15 min after glucose 
loading, compared with the NC. Similarly, the 
treated groups exhibited some improvements in 
glucose tolerance (GT) at 15 min, but these 
differences were not significant. The 95 and 50 
% (v/v) ethanol extracts afforded only 12.41 % 
improvement in GT. GTs were 5.4, 10.64, and 
11.73 % after administration of 75 and 25 % (v/v) 
ethanol and aqueous extracts, respectively 
(Table 3). 
 
Effects of multiple-dose M. oleifera 
extracts in diabetic rats 
 
The ethanol (95, 75, 50, and 25 % [v/v]) and 
aqueous extracts, metformin, significantly 
reduced the BG levels on days 7 and 14 after 
overnight fasting (p < 0.001; Figure 1). On day 7, 
the 50 and 25 % (v/v) extracts reduced the BG 
concentration by 55.35 and 54.57 %, whereas 
the reduction afforded by the 95 % (v/v) extract 
was 64.07 % compared with the control. 
Likewise, the aqueous extract afforded a 60.06 
% reduction in BG level compared with the initial 
value (19.28 ± 0.36 mmol/L). 
 
Effects of single-dose M. oleifera extract 
in diabetic rats 
 
Metformin afforded 42.87 % reduction in 
hyperglycaemia, compared with the NC, 7 h after 
administration (Table 4). The 95 and 75 % (v/v) 
ethanol extracts lowered the BG level by 30.28 
and 18.05 %, respectively. The 50 and 25 % (v/v) 
ethanol extracts did not markedly reduce the BG 
level, whereas the aqueous extract lowered the 
BG level significantly to only 1 h after 
administration (p < 0.05). 
 












Physical appearance  Yield (%) 
95% (1000:0) 800 184.45 Black-greenish and sticky 
and oily 
23 
75% (789: 211) 800 214.96 Dark brown and sticky 26.87 
50% (526: 474) 800 192.76 Dark brown and sticky 24.01 
25% (263: 737) 800 253.81 Dark brown and sticky 31.72 
Water (0:1000)        800 217.75 Dark brown 27.22 
 
Table 2: Effect of M. oleifera extracts in normal rats (n=6)  
 
Sample/extract Dose/kg  Blood glucose levels after treatment (mmol/L) 
  0 (FBG) 1 3 5 7 
NC 10mL 5.1±0.46 4.98±0.60 5.01±0.68 5.06±0.44 5.13±0.58 
G 10mg 4.96±0.33 3.81±0.94a 3.75±0.77b 3.45±0.19c 4.1±0.43a 
E 95% 1000mg 4.95±0.48 5.38±0.61 5.67±0.44 5.22±0.44 5.11±0.65 
E 75% 1000mg 5.15±0.48 5.52±0.52 5.62±0.53 5.28±0.55 4.75±0.74 
E 50% 1000mg 5.15±0.50 5.33±0.36 5.43±0.43 5.15±0.23 5.01±0.51 
E 25% 1000mg 4.88±0.44 5.4±0.76 5.83±0.66 4.95±0.82 5.07±0.48 
AE 1000mg 5.13±0.54 5.97±0.30 5.83±0.32 5.4±0.52 5.06±0.83 
FBG=fasting blood glucose, NC=negative control, G=glibenclamide, E=ethanol, AE=aqueous extract, a p<0.05, b 
p<0.01, c p<0.001, treated groups were compared with NC 
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weight FBG Blood glucose levels after treatment (mmol/L)) 
  0 min 15 min 30 min 45 min 60 min 90 min 120 min 
NC 10mL 5.22±0.19 7.33±0.92 6.38±0.50 5.38±0.35 5.12±0.20 4.97±0.19 4.77±0.29 
G 10mg 5.47±0.31 4.58±1.13c 3.75±0.66c 3.57±0.70c 3.3±0.47c 2.88±0.34c 2.68±0.29c 
M 500mg 5.5±0.54 6.53±0.53 5.7±0.30 5.33±0.33 5.17±0.30 4.92±0.40 4.67±0.53 
E 95% 1000mg 5.25±0.45 6.42±0.60 5.77±0.30 5.63±0.36 5.48±0.34 5.25±0.38 5.1±0.39 
E 75%  1000mg 5.2±0.49 6.93±0.90 6.18±0.49 5.78±0.64 5.45±0.37 5.05±0.24 4.87±0.32 
E 50% 1000mg 5.47±0.38 6.42±0.86 5.82±0.43 5.22±0.34 5.08±0.31 4.98±0.31 4.88±0.55 
E 25% 1000mg 5.33±0.50 6.55±1.08 6.07±0.63 5.32±0.31 5.38±0.48 4.93±0.12 4.73±0.27 
AE 1000mg 5.23±0.28 6.47±0.69 5.67±0.27 5.42±0.35 5.25±0.34 4.93±0.12 4.85±0.29 
NC=negative control, G=glibenclamide, M=Metformine, E=ethanol, AE=aqueous extract, FBG=fasting blood 
glucose, Statistically compared with NC,  a p < 0.05, b p < 0.01, c p < 0.001 
 
Table 4: Effects of single dose M. oleifera extracts in diabetic rats (n = 6) 
 
Group Dose FBG Blood glucose levels after treatment (mmol/L)  
  (per kg)  0h 1 h 3 h 5 h 7 h 
NDC 10mL 20.35±1.90 21.58±1.59 20.25±1.66 20.22±0.93 20.48±1.77 
M 500mg 20.20±0.98 18.93±1.23a 17.23±2.06b 15.45±1.18c 11.7±0.96c (42.08%) 
E 95% 1000mg 19.85±2.71 18.58±2.77a 17.13±1.86b 15.92±2.44c 13.84±2.41c (30.28%) 
E 75% 1000mg 20.28±1.31 20.27±0.85 18.40±0.40 17.07±0.80b 16.62±1.33b (18.05%) 
E 50% 1000mg 18.50±0.44 19.30±0.64 19.10±1.04 18.47±0.77 18.68±0.61 
E 25% 1000mg 19.52±1.62 19.20±0.49 19.07±0.47 19.55±1.40 18.83±1.56 (3.53%) 
AE 1000mg 19.28±0.73 18.63±2.32a 18.33±1.87 18.22±0.89 18.03±0.57 (6.48%) 
NDC (negative diabetic control), M (metformin treated positive control), E (ethanol) and AE (aqueous extract), a p 
< 0.05, b p < 0.01, c p < 0.001, FBG (fasting blood glucose). Statistically, the standard drug and extract treated 
groups were compared with NDC 
 
 
Figure 1: Effects of multiple-dose M. oleifera extracts in diabetic rats. NDC-negative diabetic control, 
PDC-positive diabetic control, E-ethanol extract. The results of PDC and different aqueous-ethanol 
extracts were statistically compared with NDC, c p<0.001. 
 
Effects of M. oleifera fractions in diabetic 
rats  
 
Diabetic rats that received the butanol fraction 
developed significant (p < 0.01) acute anti-
hyperglycaemic activity. No other fraction was 




The active butanol fraction and the 95 % (v/v) 
ethanol extract contained abundant flavonoids, 
glycosides, tannins, and phenols (Table 6). The 
aqueous extract lacked alkaloids and terpenoids, 
whereas hexane fraction contained only tannins 
and phenols. 
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Thin layer chromatogram 
 
Figure 2 shows three prominent spots in the 95 
% (v/v) ethanol extract and the butanol fraction. 
These were identified as quercetin 3-β-D-
glucoside, kaempferol 3-O-glucoside, and 
cryptochlorogenic acid (Figure 3), with Rf values 
of 0.658, 0.711, and 0.316, respectively. 
 
Identified compounds and validation 
results 
 
HPLC chromatograms of the active 95 % (v/v) 
ethanol extract, the butanol fraction, and the 
standard mixture are shown in Figure 4. 
Compound identification was based on the 
absorption spectra, retention times, and peak 
 
Table 5: Effects of M. oleifera fractions in diabetic rats 
 
Group Dose FBG Blood glucose levels after treatment (mmol/L)  
 (n=6) per kg 0 h 1 h 3 h 5 h 7 h 
NDC  10mL 20.92±2.55 21.02±2.28 20.08±1.73 19.10±1.90 20.68±2.98 
PDC  500mg 18.40±2.28 15.77±1.58b 13.93±1.96c 12.85±1.94b 10.22±1.49c 
HF 500mg 20.92±1.82 19.83±1.62 21.15±0.87 19.83±1.19 19.98±1.59 
CF 500mg 18.30±2.55 21.15±2.49 20.17±1.65 19.22±1.77 18.42±2.09 
EAF 500mg 18.13±0.67 19.58±1.38 18.90±1.50 19.65±2.89 18.33±0.95 
BF 500mg 20.52±1.23 20.1±2.31 17.67±1.93 18.43±3.48 16.00±1.27b 
AF 500mg 19.50±3.81 20.85±2.81 19.70±2.78 18.37±3.41 18.12±1.93 
NDC-negative diabetic control, PDC-positive diabetic control, HF-hexane fraction, CF-chloroform 
fraction, EAF-ethyl acetate fraction, BF-butanol fraction, AF-aqueous fraction, b (p<0.01), c (p<0.001), 
Groups were compared with NDC 
 
Table 6: Phytochemical profile of M. oleifera extracts and fractions 
 
Sample Saponins Tannins and 
phenols 
Flavonoids  Alkaloids  Terpenoids  Glycosides  
E 95% + + ++ + + ++ ++++ - - + + 
E 75% + ++ + ++ +++ - - + ++ 
E 50% ++ ++ +++ - - + ++ 
E 25% ++ ++ ++ - - +  
W 
100% 
+ + + - - + + 
Active  95% extract fraction 
HF - + ++ - - - -  
CF + + ++ - - - + + 
EAF - + + + ++ - - + ++ 
BF - + + ++ - - + ++ 
AF - + + + - - + + 
‘E’-ethanol, ‘W’-water, , (+) sign indicate intensity of reaction, ++++ (very high), +++ ( high), ++ 
(medium), + (low), (-) indicates absence of phytochemicals, HF-hexane fraction, CF-chloroform 




Figure 2: Chromatograms of M. oleifera extract, fraction, and identified compounds. EE-ethanol 
extract, BF-butanol fraction, TLC chromatogram at 254 (A) and at 366 nm (B). 
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Figure 3: Chemical structures of identified 
compounds in M. oleifera extract and fraction 
 
heights. Kaempferol-3-O-glucoside was present 
at high levels in the active 95 % (v/v) ethanol 
extract and the butanol fraction (56.58 and 
216.69 µg/mL, respectively). The potential anti-
diabetic cryptochlorogenic acid content of the 
butanol fraction was 25.74 µg/mL (Table 7). The 
limits of detection for cryptochlorogenic acid, 
quercetin 3-β-D-glucoside, and kaempferol-3-O-
glucoside were 1.515, 1.816 and 1.862 µg/mL, 
respectively. The limits of quantification were 
4.590, 5.503, and 5.642 µg/mL, respectively 
(Table 8). 
 
Intra-day accuracy (repeatability) values were 
from 98.08 - 100.37 % for cryptochlorogenic acid, 
96.07 - 101.90 % for quercetin 3-β-D-glucoside, 
and 95.92 - 101.49 % for Kaempferol-3-O-
glucoside. Intra-day precision values were 0.43 - 
1.72 % for cryptochlorogenic acid, 0.88 - 1.68 % 
for quercetin 3-β-D-glucoside, and 1.27 - 1.91 % 
for kaempferol-3-O-glucoside. Inter-day accuracy 
values were 94.02 - 101.44 % for 
cryptochlorogenic acid, 94.11 - 101.72 % for 
quercetin 3-β-D-glucoside, and 95.06 - 101.77 % 
for kaempferol-3-O-glucoside. Similarly, the inter-
day precision values were 0.44 - 2.09 % for 
cryptochlorogenic acid, 1.28 - 2.05 % for 
quercetin 3-β-D-glucoside, and 0.55 - 1.91 % for 




Anti-diabetic herbal therapies are very important 
in the field of ethno-pharmacology. Currently, 
such therapies are urgently needed to replace 
oral hypoglycaemic drugs, which are increasingly 
unable to control all pathological symptoms of 
diabetes, and are often unavailable in remote 
areas [14]. We evaluated aqueous ethanol 
extracts of M. oleifera in normal and 
streptozotocin-induced diabetic rats to identify 
possibly relevant compounds. 
 
The rises in BG levels of normal rats after 
administration of M. oleifera extracts may be 
attributed to the plant material’s content of a high 
proportion of carbohydrates. Previous studies 
showed that the 90 % (v/v) ethanol extract 
contained 45.43 % carbohydrates [15].  
 
The aqueous-ethanol extracts (95, 75, 50, 25 % 
[v/v] ethanol and 100 % water) did not exhibit a 
hypoglycemic effect or affect intraperitoneal GT 
in normal rats. This lack of effect may be 
because homeostasis was intact; plant extracts 
did not interfere with the normal regulation of 
carbohydrate metabolism [16]. An earlier study 
[17] also showed no hypoglycaemic effect in 
normal Wister rats. Data from earlier studies 
differ somewhat from ours in terms of indications 
of a hypoglycaemic effect in normal rats; this 
discrepancy may be attributable to the use of 
different rat strains, climatic variation in M. 
oleifera species, and/or the doses given. 
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Figure 4: HPLC chromatograms of M. oleifera ethanol extract (A), butanol fraction (B) and standard compounds 
(C), Peaks of cryptochlorogenic acid (1), quercetin 3-β-D-glucoside (2) and kaempferol-3-O-glucoside (3) 
 









Active 95% ethanol extract 5.16 23.90 56.58 
Active butanol fraction 25.74 159.81 216.69 
 









Cryptochlorogenic acid 12.5-200 0.9991 8.64 1.515 4.590 
Quercetin 3-β-D-glucoside 12.5-200 0.9999 12.64 1.816 5.503 
Kaempferol 3-O-glucoside 12.5-200 0.9998 13.95 1.862 5.642 
 
Table 9: Inter-day (between day) and intra-day (within day) accuracy and precision of standards 
(cryptochlorogenic acid, quercetin 3-β-D-glucoside and kaempferol-3-O-glucoside) 
 
Biological marker Concentration 
(µg/mL) 
Inter-day Intra-day 








12.5 94.02 1.66 98.08 0.85 
25 99.00 2.09 99.76 1.47 
50 101.44 1.61 100.37 1.72 
100 100.76 0.44 100.28 0.43 
200 99.76 0.15 99.92 0.78 
Quercetin 3-β-D-
glucoside 
12.5 94.11 1.28 96.07 1.68 
25 99.82 1.90 97.47 1.18 
50 99.65 1.60 101.90 1.47 
100 101.72 1.41 100.60 1.63 
200 99.62 2.05 99.79 0.88 
Kaempferol-3-O-
glucoside 
12.5 95.06 1.57 98.14 1.91 
25 97.58 1.61 95.92 1.27 
50 100.60 1.84 100.97 1.70 
100 101.77 1.91 101.49 1.65 
200 99.58 0.55 99.64 1.79 
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We found that the 95 % (v/v) ethanol extract and 
the butanol fraction thereof were the most active 
extract and fraction, respectively, exerting very 
significant acute anti-hyperglycaemic activities in 
diabetic rats. These effects may be attributable to 
the expression of glucose transporter-4 (GLUT-4) 
in the cell membrane, which promotes glucose 
uptake by skeletal muscle cells and inhibition of 
glucose synthesis in hepatic cells [18]; skeletal 
muscle cells constitute 70 % of the total body 
mass [19]. The results of multiple dosing were in 
agreement with those of a previous study [20] of 
the anti-diabetic potential of M. oleifera aqueous 
ethanol extracts (p < 0.001). The anti-
hyperglycaemic effect was greater on day 7 than 
on day 14, possibly attributable to a reduction in 
appetite and induction of other anti-diabetic 
mechanisms.  
 
Initially, we tested various isocratic and gradient 
systems in terms of optimum separation of 
compounds using a mobile phase (0.1 % [v/v] 
formic acid and acetonitrile). The isocratic 
method did not adequately separate phenolic 
compounds; only the gradient method produced 
well-resolved sharp peaks that absorbed at 344 
nm.  
 
Linearity was evident over the range of 12.5 - 
200 µg/mL for cryptochlorogenic acid, quercetin 
3-β-D-glucoside, and kaempferol-3-O-glucoside 
[r2 = 0.9991 (y = 3.1452x + 3.0369), r2 = 0.9999 
(y = 3.1485x - 1.8511), and r2 = 0.9998 (y = 
1.1045x + 0.0278) respectively; time vs. peak 
height in mAU]. The data shown in Table 9 
confirm the validity of the HPLC method in terms 
of intra-day and inter-day precision, accuracy, 
and repeatability. TLC also identified 
isoquercetin, astragalin, and crypto-chlorogenic 
acid in the 70 % [v/v] ethanol extract of M. 




The anti-hyperglycaemic effect of the M. oleifera 
95 % (v/v) ethanol extract and the butanol 
fraction thereof in diabetic rats may be 
attributable to cryptochlorogenic acid, quercetin 
3-β-D-glucoside, and kaempferol-3-O-glucoside. 
This extract, and the compounds mentioned, 
may be alternative treatments for diabetes, and 
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